Sanofi (Sanofi) Total Stockholders Equity

: $78,688 Mil (As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

Sanofi's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $78,688 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sanofi's Book Value per Share for the quarter that ended in Jun. 2023 was $31.44. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sanofi's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.29.

Sanofi (NAS:SNY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sanofi's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(78687.974	-	0)	/	2502.97
	=	31.44

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sanofi's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5359.697	+	17421.452)	/	78687.974
	=	0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sanofi's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.